However, the percentage of TAMs with FcγR remaining available (FcγR+ TAMs/total TAMs) for ex vivo interaction with the PE-conjugated, nonspecific goat anti–rabbit IgG was significantly lower in the tumor samples from the cohort with 2.4G2 antibody treatment (16.6% ± 5.0%) than in the tumor samples from the cohort without 2.4G2 antibody treatment (32.7% ± 6.2%). Here, FCGR2A is linked to neoplasm.